||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Reneuron Share Discussion Threads
Showing 13851 to 13873 of 13875 messages
|Think I may take the plunge and buy some of these. Could be a stressful journey but nothing ventured and all that...|
|;-) Like that.
I ran it past a well known Ophtha friend of mine and he said it could do very well, but its a punt. Figured, with the other products it has to, why not.|
|Interesting list of posts. I cannot quite understand the drift but...
Best wishes to all.
|Welcome on board buddy. Your as equally stupid as I am|
|Right, I'm in... Lets roll!|
|"NOMADS have NO integrity; They suck blood and fees, stifeling the PIs"
Poor grammar and an even worse attempt at a pun.|
|NOMADS have NO integrity; They suck blood and fees, stifeling the PIs|
|Just to advise further that Stifel is RENE's NOMAD.
So they either have the inside track or a motive.
Target price 15p
'We value ReNeuron using a risk-adjusted NPV, suggesting a target
price of 15p. This places no value on the CRD or exosome
programmes – the exosome platform in particular is an exciting new
therapy field where ReNeuron is leading development, and is thus
likely to represent significant upside to our valuation in the event of a
deal or positive clinical trial results.
Risk to our investment case include clinical trial delays or negative
clinical trial results. ReNeuron will also be reliant on funding or
partnership deals once its current cash has expired in 2H18.'|
|Guess you will have to look up Reneuron on either lse or iii sites to watch the proactive micheal hunt interview|
|Micheal Hunt interview c/o mol iii site
|Goo news.....Motley Fool update...c/o oil prince iii site
|Shareholders have to keep the pressure on the management to keep it as honest as a
man with previous form can be to avoid selling the company cheap having been derisked
if they get there, with your money
Market not impressed|
|Yes, there's a pulse.|
|Thank you for your email and for your support as a shareholder of ReNeuron.
ReNeuron is aware of the video posted on social media and can confirm that the company was not involved in making it or had prior knowledge of its publication.
ReNeuron is the sponsor of the Phase I/II clinical trial in RP, a role in which it provides the drug product and finances the trial but is not directly involved with study participants.
Whilst it isn’t appropriate for ReNeuron to comment on the content of the video, please rest assured that ReNeuron will announce clinical data from the RP study, and other clinical programmes, in a timely manner through the conventional regulatory channel of RNS.
I would make the general point that the results of clinical trials are based on statistical analysis of all patients that complete a trial. A single patient, even in a small study, is not necessarily representative of the overall study results - that could only be known in hindsight. All trials, even late stage ones, have non-responders to the potential treatment being studied.
A further general point on early stage trials is that they are designed to inform later studies by establishing safety, tolerability and frequently dosage. For example, the Phase II part of the current Phase I/II trial in RP will be conducted at the highest safe dose in RP patients with a greater level of vision.|
|where is the video? If it were misleading they would have gone to court to take it off circulation. The reply is significant. No denial ,disassociation with no defence. BAD|
|The same applies to you too, stevedd. The answer to your question is 'yes they do'.|
|Why do you ask stewart_25? Haven't you written your money off on this one yet?
But, if you really need to know, why not read some of the preceeding posts which people have helpfully contributed here?|
|what is with the video? content? impact on rene?|
|Somebody is systematically ditching big lumps. Its been going on for a while. I hope the Bod are not being complicit in their silence!|
|I haven't heard of this video. Does anybody have a link or an overview of the content?|